secwatch.observer — SEC 8-K summary
======================================

Issuer:     Invivyd, Inc. (IVVD)
CIK:        0001832038
Form:       8-K
Filed at:   2024-04-04T23:59:59+00:00
Accession:  0001193125-24-087408
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Invivyd announces PEMGARDA commercial launch, 2024 revenue guidance $150M-$200M
-------------------------------------------------------------------------------

- PEMGARDA now commercially available in the U.S. for COVID-19 PrEP in immunocompromised adults/adolescents.
- 2024 net product revenue guidance of $150M to $200M.
- Expects to end 2024 with at least $55M in cash and cash equivalents.
- Received FDA EUA on March 22, 2024; product available for order within two weeks.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1832038/000119312524087408/0001193125-24-087408-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1832038/000119312524087408/d818209d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-087408

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer